Biotech valuation sensitivity analysis tests how much an estimated value changes when the assumptions change. Peak sales, launch timing, development expenditure and discount rates deserve separate attention because each affects a different part of the cash flow forecast. A drug can reach its projected peak sales and still produce a disappointing return if the launch arrives late, the commercial operation costs more than expected, or too much new capital is needed along the way.
The objective is to identify what an investment case depends on. A single estimate from a risk-adjusted net present value model conceals those dependencies. Sensitivity tests expose them, showing whether a valuation survives reasonable changes or requires almost every assumption to work in the investor’s favor. The calculations below use a hypothetical drug, with deliberately simplified economics. They illustrate the method, rather than estimate the value of an actual company.
Separate Sensitivity Tests From Scenarios
A one-variable sensitivity test changes one input while holding the others constant. Reducing peak sales from $1 billion to $600 million, for example, isolates the effect of a smaller revenue opportunity. A two-variable table changes two inputs together, such as peak sales and the discount rate. These tests answer narrow questions well. They do not describe a complete business outcome, because a lower sales forecast may also require changes to staffing, manufacturing capacity and working capital. Holding those items constant is useful for diagnosis, provided the restriction remains visible.
A scenario changes a connected set of assumptions. A delayed launch might arrive after a competing treatment, face heavier rebates and require another year of development spending. That combination belongs in a scenario, rather than a test labeled “launch delayed by one year.” Keep clinical success probabilities separate during the initial commercial tests so that their effects remain distinguishable. The methods for estimating clinical and regulatory success probabilities address a different question: how likely the asset is to reach the point where those commercial assumptions matter.
Build a Base Case That Can Be Reproduced
Start with an explicit valuation date, annual cash flow schedule and definition of value. For this example, time zero is the valuation date, and all subsequent cash flows occur at year end. The company owns the drug’s full commercial economics. Sales convert into after-tax operating free cash flow before financing, with ongoing operating expenses and reinvestment already reflected in the conversion percentage. Remaining development and setup expenditure is treated as an immediate payment. That last assumption keeps the arithmetic transparent; a working investment model should schedule those payments when they are expected to occur.
| Input | Illustrative assumption |
|---|---|
| Peak annual net sales | $1 billion |
| Sales schedule | $250 million, $500 million, $750 million, $1 billion and $1 billion in years 5–9 |
| Operating free cash flow conversion | 40% of net sales |
| Probability of reaching commercialization | 60%, held constant across the initial tests |
| Remaining development and setup expenditure | $180 million, paid at time zero |
| Discount rate | 12% annually |
| Value after the modeled commercial window | Zero; no terminal value |
Before probability weighting, the annual operating cash flows are $100 million, $200 million, $300 million, $400 million and $400 million. Multiplying each by 60% produces expected commercial cash flows of $60 million, $120 million, $180 million, $240 million and $240 million. Discounting these amounts from years 5–9 at 12% gives a commercial present value of approximately $359.7 million. Subtracting the $180 million immediate expenditure produces an asset value of $179.7 million. This is neither enterprise equity value nor a share price.
The five-year commercial window is an arithmetic shortcut, not a forecast of a typical drug lifecycle. Its cash flows move together when launch timing changes below. A full model should forecast the relevant commercial life, including declining sales where appropriate. It should also probability-weight future development expenditure by the chance of reaching the stage where that expenditure occurs. Applying the final commercialization probability to every cost would understate payments made before failure becomes apparent. Historical spending is sunk, it should not be deducted again as future expenditure.
Test Peak Sales Through Its Underlying Drivers
Peak sales is an output that deserves its own supporting forecast. For a recurring treatment, annual net sales can be built from treated patient equivalents and net revenue per patient. The patient estimate should reflect eligibility, diagnosis, access, treatment uptake and persistence without counting the same restriction twice. An assumed market share cannot repair an inflated patient population. Work through the addressable market and eligible patient population before deciding which peak sales range belongs in the valuation. Otherwise, a neatly formatted sensitivity table simply gives an unsupported market estimate more decimal places.
Separate patient volume from price. A forecast of 10,000 treated patient equivalents at $100,000 net revenue each produces $1 billion in annual sales. Reaching $1.4 billion could mean treating 14,000 patient equivalents at the same price, collecting $140,000 each from 10,000, or some combination. Those paths require different evidence. Greater volume may require more treatment capacity; higher net revenue may face payer resistance. Build price assumptions after expected deductions, rather than using a headline list price as collected revenue. The distinction belongs in the analysis of drug pricing, reimbursement and market access.
In the illustrative model, reducing peak sales to $600 million scales the entire revenue curve to 60% of its original level. Commercial present value falls to $215.8 million, leaving asset value of just $35.8 million after the unchanged $180 million expenditure. A 40% reduction in peak sales therefore removes about 80% of asset value. Fixed expenditure explains the difference. This relationship is intentionally simple: the cash conversion percentage does not change with sales. In a fuller model, operating costs should distinguish variable expenses from commitments that remain even when revenue disappoints.
Test Launch Timing Without Moving Every Date Automatically
A pure timing test moves commercial cash flows while preserving their amounts and duration. Shifting the example’s five commercial payments back by one year reduces their present value from $359.7 million to $321.2 million. After the unchanged immediate expenditure, asset value falls from $179.7 million to $141.2 million, a reduction of approximately 21.4%. The commercial cash flows themselves lose only 10.7% of present value. Again, the fixed expenditure makes the percentage change in net asset value larger. This first calculation measures waiting, nothing else.
Next, test whether the commercial window actually moves with the launch. If an assumed competitive entry date remains fixed, a delay can remove a profitable year rather than postpone it. Do not shift a patent expiry assumption forward simply because development has taken longer. Keep the underlying protection dates and commercial erosion assumptions separate, then test the consequences of a shorter selling period. The treatment of patents and regulatory exclusivity should support the forecast’s dates. A model that moves every commercial boundary together can make a delay look much less expensive than the underlying scenario warrants.
Launch timing also needs an operational definition. Vertex’s 2024 Form 10-K reported $10 million of CASGEVY product revenue for that year and described revenue recognition for its gene therapy products as occurring upon infusion. The filing also described the collection, manufacturing and treatment steps preceding infusion. Those historical disclosures illustrate why patient initiation and recorded sales need separate schedules; they do not establish the product’s later performance. The supporting evidence is in Vertex’s 2024 annual report and revenue recognition disclosures.
For valuation purposes, distinguish regulatory approval, commercial availability, first recognized revenue and sustained adoption. A treatment might become available on the assumed date yet take longer to reach the forecast sales ramp. Test that possibility independently: keep the first sales date unchanged, reduce early revenue and extend the time to peak. The work on drug launches and treatment adoption provides the commercial context. In the spreadsheet, the practical requirement is straightforward. “Launch year” should not silently control every event between approval and mature sales.
Separate Development Costs From Commercial Cash Conversion
Remaining development expenditure and operating cash conversion affect value differently. An additional $40 million payment at time zero reduces the example’s asset value by exactly $40 million. Reducing cash conversion from 40% to 30%, however, affects every commercial year. Commercial present value falls to approximately $269.8 million and asset value, to $89.8 million. That is roughly half the base-case asset value. Describe this change as a ten percentage point reduction in conversion, not a 10% reduction. The latter would mean a move from 40% to 36%, a much smaller adjustment.
Do not treat manufacturing readiness as a cost assumption alone. FDA drug approval includes an assessment of manufacturing processes and facilities, and unacceptable facility compliance can affect approval of applications listing that facility. The FDA’s pharmaceutical inspections and compliance requirements support treating readiness as a potential timing dependency. In a valuation scenario, the consequences might include corrective expenditure and a later revenue start. The source establishes the regulatory consideration; the size and duration of any modeled consequence must come from evidence about the asset being valued.
Build commercial costs from the operating model rather than assigning an attractive margin because another company achieved one. Test production yield, unused capacity and inventory requirements where they affect cash generation. A lower manufacturing cost per unit may require more capital expenditure first. A smaller sales organization may reduce spending while also slowing uptake. The assessment of biotech manufacturing costs and capacity should connect these assumptions. Avoid counting the same investment twice, once in development or setup expenditure and again through an unexplained deduction from operating cash flow.
Ownership of the economics matters just as much. A company receiving royalties does not retain all the drug’s sales, and a company paying royalties cannot value those payments as though they belong to shareholders. Include contractual milestones when the modeled conditions trigger them, using the appropriate timing and probability. Do not add a deal’s maximum announced milestone total to present value. A separate review of licensing payments, milestones and royalties can establish those obligations before sensitivity testing begins. The table above assumes full commercial ownership only to avoid mixing contractual structures into the arithmetic.
Use Discount Rates Consistently
The discount rate must match the cash flow being valued. Operating free cash flow before debt payments belongs with a cost of capital framework; cash flow available to equity holders after financing belongs with a cost of equity framework. Nominal cash flows also require a nominal rate in the same currency. These consistency requirements are set out in NYU Stern’s valuation framework for cash flows and discount rates. A sensitivity test cannot fix a mismatch. Moving an unsuitable rate through a wider range produces more outputs, not a better valuation.
Clinical failure probability and the discount rate should have separate jobs. If expected cash flows already reflect the possibility that a drug never reaches commercialization, adding a large discount rate premium for that same failure event can count the risk twice. Probability weighting does not make the remaining cash flows risk free, either. The task is to identify what each adjustment captures. This distinction is developed in Aswath Damodaran’s analysis of failure risk and discount rate double counting. Record the rationale instead of treating a high rate as a general allowance for everything uncertain.
For the hypothetical drug, changing the rate from 12% to 10% increases asset value to $231.1 million. Raising it to 14% reduces value to $135.7 million. These rates are illustrative, not a current estimate of any company’s financing cost. To interpret the range, separate changes in operating expectations from changes in required returns. A weaker financing market might affect both, but the mechanisms differ. The discussion of biotech funding conditions and market cycles provides context without requiring every deterioration in sentiment to become an arbitrary rate premium.
Read a Two-Variable Sensitivity Table
The table below combines peak sales and discount rates while preserving the original sales ramp, 40% cash conversion, 60% commercialization probability and $180 million immediate expenditure. Every cell is an asset value, expressed in millions of dollars. None includes corporate cash or debt. Reading across a row isolates the discount rate effect; reading down a column isolates the sales effect. Moving diagonally changes both. Keeping that distinction clear prevents a favorable corner from becoming a substitute for the base case.
| Peak annual net sales | 10% discount rate | 12% discount rate | 14% discount rate |
|---|---|---|---|
| $600 million | $66.7 | $35.8 | $9.4 |
| $1 billion | $231.1 | $179.7 | $135.7 |
| $1.4 billion | $395.5 | $323.6 | $262.0 |
The spread between $9.4 million and $395.5 million is not a confidence interval. The table assigns no probabilities to its inputs, and its endpoints are chosen assumptions rather than statistical bounds. It also excludes combinations involving delayed launch, higher expenditure or clinical failure. Its value is diagnostic: within these chosen ranges, the sales assumption creates a larger movement than the discount rate. That observation applies to this model and these ranges. It should guide the next research question, rather than become a claim that peak sales always dominates biotech valuation.
Combine Assumptions Into Coherent Scenarios
Scenario inputs should describe an economically plausible outcome. Selecting the highest sales, lowest costs and earliest launch independently can create a business that could not operate as modeled. Stronger sales might require more commercial expenditure; discounted pricing might increase volume while reducing margin. The importance of preserving relationships between inputs is examined in NYU Stern’s research on scenario analysis, decision trees and simulations. A scenario needs a causal explanation. “Downside” is a label, not an explanation of why the assumptions move together.
Consider a downside with $600 million peak sales, 30% cash conversion, a one-year delay, a 14% discount rate and $220 million of immediate expenditure. Keeping the five-year commercial window and 60% commercialization probability produces a value of approximately negative $95.4 million. That result means the modeled commitment destroys value under those assumptions. It is not a negative share price. A realistic decision model should examine whether management could abandon, license or restructure the project before incurring every payment. Those choices may reduce losses, though they do not erase obligations already incurred.
Explain the commercial trigger behind the downside. Earlier rival entry could reduce the obtainable patient share, while weaker differentiation could require a lower net price. Those assumptions should connect to the review of competing treatments and standards of care. Keep clinical failure as a separate branch where it is already represented by the commercialization probability. Otherwise, weighting an additional failure scenario can count that event twice. If scenario probabilities are assigned, state whether they describe outcomes conditional on approval or outcomes across the entire development path.
Carry the Results Through to Funding and Per-Share Value
Asset sensitivity is only part of the shareholder calculation. A delay can lower operating value and create a funding gap before the next milestone. In the example, adding $40 million of immediate expenditure to the one-year delay reduces asset value from $141.2 million to $101.2 million. That payment still needs financing if available cash cannot cover it. Run the downside through a dated cash schedule, rather than relying on an annual average burn rate. The assessment of cash burn and runway should show when the balance becomes insufficient, not just how much expenditure remains in total.
Model a financing on both sides of the per-share calculation. In a separate simplified example, equity worth $260 million across 50 million shares equals $5.20 per share. Raising $100 million at $4 creates 25 million new shares. Before fees or other changes, equity value rises to $360 million because the company receives the cash, but value per share falls to $4.80 across 75 million shares. This illustrates share dilution and financing terms, rather than assuming that every capital raise destroys value. The issue price, proceeds and commitments all matter.
Use a consistent bridge from operating assets to equity: add corporate cash, subtract debt and account for other claims or liabilities not already captured in the cash flows. Deduct unallocated corporate costs if asset valuations exclude them. Do not subtract future development expenditure again when it is already included in asset value, or add financing proceeds without adding the corresponding shares. The treatment of enterprise value and corporate cash should remain consistent across every scenario. Otherwise, apparent operating upside can be an accounting inconsistency in disguise.
Reverse the Model to Find the Required Assumption
A reverse valuation starts with a value and solves for the assumption needed to support it. In the simplified base case, commercial present value scales directly with peak sales. At a 12% discount rate, peak sales of approximately $500 million would make asset value zero after the $180 million immediate expenditure. That is a model break-even point, not a commercial forecast. It assumes the same ramp, cash conversion, success probability and selling window. Changing any of those inputs moves the threshold. There is no need to hide that dependency behind a single “required sales” figure.
If the same asset needed to support $150 million of value, the required peak sales would be approximately $917 million under the unchanged assumptions. Research can then address a concrete question: does the patient and pricing evidence support that threshold? This is often more useful than debating whether an asset is worth $150 million or $180 million. Test the required adoption rate, net price or launch date against evidence. Where the model contains nonlinear costs, capacity constraints or changing tax payments, solve the threshold using the full cash flow schedule rather than scaling sales mechanically.
Keep an Assumption Register and a Research Queue
Each important input should have a base value, tested range, rationale and next evidence date. Rank inputs by the valuation change across a defensible range. A tornado chart can display that ranking, but its result depends on the ranges selected: a very wide sales range will naturally appear more influential than a narrow cost range. Prioritize assumptions that combine a large valuation effect with weak evidence and an approaching opportunity for clarification. The process for researching trial records, scientific papers and financial filings should feed that register with dated evidence.
- Freeze the base case. Record the valuation date, cash flow definitions and ownership assumptions.
- Run isolated tests. Change sales, timing, costs and discount rates separately before combining them.
- Build connected scenarios. State the event that causes related assumptions to change.
- Reconcile funding and shares. Check cash balances, financing proceeds and the ownership denominator.
Update the assumption affected by new evidence, then rerun the connected calculations. A slower sales ramp need not change biological success probability. A manufacturing issue may require changes to timing and expenditure before there is enough evidence to revise peak demand. Preserve earlier model versions so the change in value can be attributed to revised evidence, elapsed time or a changed method. That discipline makes the sensitivity analysis usable after the next announcement, when the temptation to move several assumptions at once is strongest.